Biopharma & Life Sciences

MacroGenics Executive Compensation (FY25)

Name: MacroGenics (MGNX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

MGNX · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Eric Risser

Latest say-on-pay support

May 19, 2026

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The MacroGenics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 4, 2026Latest filing (8-K): May 20, 2026

15 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

MacroGenics brief$500Get the executive brief

Velarion Intel, one year, every company

244 figures on this page: 233 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

This company is not required to report a chief executive pay ratio.

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive of record: Scott Koenig → Eric Risser

Frequently asked questions

Answers drawn from the data on this page.

Who is MacroGenics' chief executive and what were they paid?

Eric Risser was paid $2,078,854 in total compensation as President, Chief Executive Officer and Director for fiscal 2025.

What was MacroGenics' say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 98.1% of votes cast for or against in favor at the meeting held May 19, 2026.

Which companies are in MacroGenics' peer group?

The disclosed peer group includes 2seventy bio, Adaptimmune Therapeutics, Agenus, Inc., Arcus Biosciences and Cogent Biosciences, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Scott Koenig President, Chief Executive Officer and Director	◇	—	—	◇	◇	—	◇	◇
James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary	◇	—	—	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Scott Koenig President, Chief Executive Officer and Director	◇	—	◇	◇	◇	—	◇	◇
Stephen Eck Senior Vice President, Clinical Development and Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇
James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Scott Koenig Former Chief Executive Officer and current Director	◇	—	◇	◇	◇	—	◇	◇
Stephen Eck Senior Vice President, Clinical Development and Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇
James Karrels Senior Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Eric Risser President, Chief Executive Officer and Director	◇	◇	◇	◇	◇	—	◇	◇
Ezio Bonvini Senior Vice President, Research and Chief Scientific Officer	◇	◇	◇	◇	◇	—	◇	◇
James Karrels Senior Vice President and Chief Financial Officer	◇	◇	◇	◇	◇	—	◇	◇
Scott Koenig Former Chief Executive Officer and current Director Departed during or after this year	◇	—	—	—	—	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2023

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
James Karrels	RSU	—	—	—	◇	—	—	◇
James Karrels	OPTION	◇	—	—	◇	—	◇	◇
Scott Koenig	RSU	—	—	—	◇	—	—	◇
Scott Koenig	OPTION	◇	—	—	◇	—	◇	◇
Stephen Eck	OPTION	◇	—	—	◇	—	◇	◇
Stephen Eck	RSU	—	—	—	◇	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Eric Risser	Option	◇	—	◇	8/13/2035
	Option	◇	—	◇	2/7/2035
	Option	◇	—	◇	2/15/2023
	Option	◇	—	◇	2/8/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/22/2032
Ezio Bonvini	Option	◇	—	◇	2/7/2035
	Option	◇	—	◇	2/15/2023
	Option	◇	—	◇	2/8/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/22/2032
James Karrels	Option	◇	—	◇	2/7/2035
	Option	◇	—	◇	2/15/2033
	Option	◇	—	◇	2/8/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/22/2032
Scott Koenig	Option	◇	—	◇	2/15/2033
	Option	◇	—	◇	2/8/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/22/2032

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Ezio Bonvini

Senior Vice President, Research and Chief Scientific Officer · Employment agreement

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Scott Koenig

Former Chief Executive Officer and current Director · Severance agreement

Severance multiple	◇
Severance cash amount	◇
Benefits continuation	◇
Non-compete period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
William Heiden	◇	◇	◇	—	—	—	◇
Federica O'Brien	◇	◇	◇	—	—	—	◇
Jay Siegel	◇	◇	◇	—	—	—	◇
David Stump	◇	◇	◇	—	—	—	◇
Karen Ferrante	◇	◇	◇	—	—	—	◇
Edward Hurwitz	◇	◇	◇	—	—	—	◇
Margaret Liu	◇	◇	◇	—	—	—	◇
Scott Jackson	◇	◇	◇	—	—	—	◇
Meenu Chhabra Karson	◇	◇	◇	—	—	—	◇
Scott Koenig	◇	—	—	—	—	—	◇

Eric Risser served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

2seventy bio TSVT
Adaptimmune Therapeutics ADAP
Agenus, Inc. AGEN
Arcus Biosciences RCUS
Cogent Biosciences COGT
Fate Therapeutics FATE
G1 Therapeutics symbol not shown
Inovio Pharmaceuticals INO
iTeos Therapeutics ITOS
Karyopharm Therapeutics KPTI
Mersana Therapeutics MRSN
Precigen PGEN
Rigel Pharmaceuticals RIGL
Xencor, Inc. XNCR
Y-mAbs Therapeutics YMAB
Zymeworks, Inc. ZYME

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 19, 2026	=	◇	◇	◇
2024	May 21, 2025	=	◇	◇	◇
2023	May 21, 2024	=	◇	◇	◇
2022	May 31, 2023	=	◇	◇	◇
2021	May 19, 2022	=	◇	◇	◇
2020	May 13, 2021	=	◇	◇	◇
2019	May 14, 2020	=	◇	◇	◇
2018	May 16, 2019	=	◇	◇	◇
2017	May 17, 2018	=	◇	◇	◇
2016	May 18, 2017	=	◇	◇	◇
2015	May 18, 2016	=	◇	◇	◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Eric Risser (President, Chief Executive Officer and Director), FY2025 total compensation $2,078,854 (base salary $561,568) [exec_comp, SEC accession 0001125345-26-000021, filed 2026-04-08]

See a complete sample report

What this page does not include

Everything above is a fact MacroGenics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where MacroGenics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

244 figures on this page: 233 cited to the filing that reported them, 11 calculated from figures it prints.

233 cited to the filing

11 calculated from the filing

Documents cited

8-K, filed May 20, 2026
0001125345-26-000042
Proposal 3 . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.
DEF 14A, filed April 8, 2026
0001125345-26-000021
Compensation Discussion and Analysis · Director Compensation · Summary Compensation Table
8-K, filed May 22, 2025
0001125345-25-000075
Proposal 3 . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.
DEF 14A, filed April 11, 2025
0001125345-25-000047
Summary Compensation Table
EX-10, filed March 20, 2025
0001125345-25-000042
Exhibit
8-K, filed May 23, 2024
0001125345-24-000124
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 8, 2024
0001125345-24-000076
8-K, filed June 2, 2023
0001125345-23-000081
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 23, 2022
0001125345-22-000053
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 18, 2021
0001125345-21-000082
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 14, 2020
0001125345-20-000079
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 21, 2019
0001125345-19-000081
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 23, 2018
0001125345-18-000077
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 22, 2017
0001125345-17-000062
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 20, 2016
0001125345-16-000059
Item 5.07 Submission of Matters to a Vote of Security Holders

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “MacroGenics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MGNX (accessed 2026).

Short form: data: Velarion

The MacroGenics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

15 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/MGNX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="MacroGenics executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about MacroGenics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers MacroGenics discloses

The companies named in MGNX's own disclosed peer group.

Adaptimmune Therapeutics Agenus, Inc.Arcus Biosciences Cogent Biosciences Fate Therapeutics Inovio Pharmaceuticals iTeos Therapeutics Karyopharm Therapeutics Mersana Therapeutics Precigen Rigel Pharmaceuticals Xencor, Inc.Y-mAbs Therapeutics Zymeworks, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}